CDX2 and LI-cadherin expression in esophageal mucosa: Use of both markers can facilitate the histologic diagnosis of Barrettg's esophagus and carcinoma

International Journal of Surgical Pathology

Volumn 18, Issue 5, 2010, Pages 330-337

  Weimann, Andreas ^a   Zimmermann, Mathias ^a   Gross, Monica ^a   Slevogt, Hortense ^a   Rieger, Anja ^a   Morawietz, Lars ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Barrettg's metaplasia; CDX2; esophageal adenocarcinoma; immunohistochemistry; LI cadherin

Indexed keywords

CADHERIN; LIVER INTESTINE CADHERIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CADHERINS; ESOPHAGEAL NEOPLASMS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PRECANCEROUS CONDITIONS;

EID: 78149469531     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896910364228     Document Type: Article

References (45)

1. Barrett NR Chronic peptic ulcer of the oesophagus and "oesophagitis ". Br J Surg. 1950 ; 38: 175-182.
2. Barrett NR The lower esophagus lined by columnar epithelium. Surgery. 1957 ; 41: 881-894.
3. Sampliner RE Practice guidelines on the diagnosis, surveillance, and therapy of Barrettg's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998 ; 93: 1028-1032.
4. Weinstein WM, Ippoliti AF The diagnosis of Barrettg's esophagus: goblets, goblets, goblets. Gastrointest Endosc. 1996 ; 44: 91-95.
5. Batts KP Barrett esophagus-more steps forward. Hum Pathol. 2001 ; 32: 357-359.
6. Goldblum JR Barrettg's esophagus and Barrettg's-related dysplasia. Mod Pathol. 2003 ; 16: 316-324.
7. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 ; 265: 1287-1289.
8. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998 ; 83: 2049-2053.
9. Vizcaino AP, Moreno V., Lambert R., Parkin DM Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002 ; 99: 860-868.
10. Eloubedi MA, Provenzale D. Does this patient have Barrettg's esophagus? The utility of predicting Barrettg's esophagus at the index endoscopy. Am J Gastroenterol. 1999 ; 94: 937-943.
11. Freund JN, Domon-Dell C., Kedinger M., Duluc I. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol. 1998 ; 76: 957-969.
12. James R., Erler T., Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biochem. 1994 ; 269: 15229-15237.
13. Suh E., Chen L., Taylor J., Traber PG A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol. 1994 ; 14: 7340-7351.
14. Suh E., Traber PG An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996 ; 16: 619-625.
15. Eda A., Osawa H., Yanaka I., et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol. 2002 ; 37: 94-100.
16. Eda A., Osawa H., Satoh K., et al. Aberrant expression of CDX2 in Barrettg's epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003 ; 38: 14-22.
17. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrettg's oesophagus. J Clin Pathol. 2004 ; 57: 1063-1068.
18. Phillips RW, Frierson HF Jr, Moskaluk CA Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol. 2003 ; 27: 1442-1447.
19. Ko S., Chu KM, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol. 2005 ; 205: 615-622.
20. Mutoh H., Hakamata Y., Sato K., et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun. 2002 ; 294: 470-479.
21. Ranscht B. Cadherins and catenins: interactions and functions in embryogenic development. Curr Opin Cell Biol. 1994 ; 6: 740-746.
22. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995 ; 7: 619-627.
23. Takeichei M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993 ; 5: 806-811.
24. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998 ; 153: 333-339.
25. Berndorff D., Gessner R., Kreft B., et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol. 1994 ; 125: 1353-1369.
26. Gessner R., Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci. 2000 ; 915: 136-143.
27. Hinoi T., Lucas PC, Kuick R., Hanash S., Cho KR, Fearon ER CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002 ; 123: 1565-1577.
28. Gräparatzinger C., Kneifel J., Patschan D., et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut. 2001 ; 49: 73-81.
29. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST Identification of liver-intestine cadherin in hepatocellular carcinoma-a potential disease marker. Biochem Biophys Res Commun. 2003 ; 311: 618-624.
30. Takamura M., Sakamoto M., Ino Y., et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 2003 ; 94: 425-430.
31. Werner M., Flejou JF, Hainaut P., et al. Adenocarcinoma of the oesophagus. In: Hamilton SR, Aaltonen LA, eds. WHO Classification of Tumours, Pathology and Genetics: Tumors of the Digestive System. Lyon, France: IARC Press ; 2000: 20-26.
32. Remmele W., Stegner HE Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987 ; 8: 138-140.
33. Haggit RC Barrettg's esophagus. Hum Pathol. 1994 ; 25: 982-993.
34. Conio M., Lapertosa G., Blanchi S., Filiberti R. Barrettg's esophagus: an update. Crit Rev Oncol Hematol. 2003 ; 46: 187-206.
35. Falk GW Barrettg's esophagus. Gastroenterology. 2002 ; 122: 1569-1591.
36. Phillips RW, Wong RK Barrettg's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am. 1991 ; 20: 791-816.
37. Jankowski JA, Odze RD Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol. 2009 ; 104: 1093-1096.
38. Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M., Tilanus HW Dysplasia and aneuploidy as markers of malignant degeneration in Barrettg's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut. 1994 ; 35: 1348-1351.
39. Reid BJ, Levine DS, Longton G., Blount PL, Rabinovitch PS Predictors of progression to cancer in Barrettg's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000 ; 95: 1669-1676.
40. Fléjou JF, Svrcek M. Barrettg's oesophagus-a pathologistg's view. Histopathology. 2007 ; 50: 3-14.
41. Sikkema M., Kerkhof M., Steyerberg EW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrettg's esophagus: a case-control study. Am J Gastroenterol. 2009 ; 104: 2673-2680.
42. Läpararinc E., Jakobsson B., Landberg G., Veress B. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrettg's oesophagus. Histopathology. 2005 ; 46: 642-648.
43. Ko S., Chu KM, Luk JM, et al. Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun. 2004 ; 319: 562-568.
44. Feith M., Stein HJ, Mueller J., Siewert JR Malignant degeneration of Barrettg's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus. 2004 ; 17: 322-327.
45. Lorentz O., Cadoret A., Duluc I., et al. Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene. 1999 ; 18: 87-92.